Vaccine for human respiratory syncytial virus on the horizon

Source: Hipersynteza/Science Photo Library

A vaccine against human respiratory synctial virus (pictured) is being researched by a team in Belgium

Human respiratory syncytial virus (HRSV) is a major cause of respiratory tract infections in infants. High-risk children may receive prophylactic palivizumab therapy; however, no effective antiviral or anti-inflammatory treatment exists.

A vaccine against HRSV may now be on the horizon, following work by Bert Schepens and Xavier Saelens from Ghent University, Belgium, and team, published in EMBO Molecular Medicine[1]
(online, 8 October 2014). They have developed a vaccine based on the extracellular domain of the Small Hydrophobic protein (SHe) of HRSV and found that it induced immune protection in mice and rats, acting via a mechanism that differs from the natural immune response.

“The SHe-based vaccine could be linked to other candidate vaccines directed against the larger envelope proteins of the virus, to double hit the virus,” the researchers suggest. 



[1] Schepens B, Sedeyn K, Vande Ginste L et al. Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein. EMBO Molecular Medicine 2014. doi: 10.15252/emmm.201404005 (accessed 8 October 2014).

Last updated
The Pharmaceutical Journal, PJ, 1 November 2014, Vol 293, No 7834;293(7834):DOI:10.1211/PJ.2014.20066949

You may also be interested in